AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|AAPL319.29-8.92 (-2.72%) ▼|ABBV257.28-2.93 (-1.13%) ▼|ABT109.88+1.09 (+1.00%) ▲|ACN188.07-5.05 (-2.62%) ▼|ADBE267.50-18.25 (-6.39%) ▼|AMAT454.82+18.91 (+4.34%) ▲|AMD469.36+13.20 (+2.89%) ▲|AMGN437.81-6.31 (-1.42%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN255.93-2.97 (-1.15%) ▼|AVGO355.98-1.19 (-0.33%) ▼|AXP326.30-3.52 (-1.07%) ▼|BA210.42-0.09 (-0.04%) ▼|BAC62.02-0.70 (-1.12%) ▼|BKNG193.95-1.19 (-0.61%) ▼|BLK1,119.55-6.60 (-0.59%) ▼|BMY66.94-1.15 (-1.69%) ▼|BNY164.42+0.09 (+0.05%) ▲|BRK-B506.39-1.74 (-0.34%) ▼|C135.61-2.53 (-1.83%) ▼|CAT813.09+12.95 (+1.62%) ▲|CL89.84-0.26 (-0.28%) ▼|CMCSA26.46-0.20 (-0.73%) ▼|COF219.53-0.97 (-0.44%) ▼|COP134.42-1.30 (-0.96%) ▼|COST916.97-8.44 (-0.91%) ▼|CRM259.49-4.94 (-1.87%) ▼|CSCO109.14+0.53 (+0.49%) ▲|CVS96.97-0.24 (-0.24%) ▼|CVX208.62-2.70 (-1.28%) ▼|DE696.80+2.39 (+0.34%) ▲|DHR207.00-4.04 (-1.91%) ▼|DIS105.45-1.71 (-1.60%) ▼|DUK121.12-0.28 (-0.23%) ▼|EMR152.34+2.13 (+1.42%) ▲|FDX322.70-1.61 (-0.50%) ▼|GD359.51-6.36 (-1.74%) ▼|GE333.36-0.13 (-0.04%) ▼|GEV944.08+2.24 (+0.24%) ▲|GILD150.45-0.78 (-0.51%) ▼|GM87.33+0.29 (+0.33%) ▲|GOOG334.30-4.78 (-1.41%) ▼|GOOGL337.61-4.65 (-1.36%) ▼|GS1,025.29-12.64 (-1.22%) ▼|HD319.34+1.27 (+0.40%) ▲|HON208.23+0.60 (+0.29%) ▲|IBM234.15-0.57 (-0.24%) ▼|INTC95.01+3.34 (+3.64%) ▲|INTU333.77-10.53 (-3.06%) ▼|ISRG365.59-4.24 (-1.15%) ▼|JNJ276.25-2.18 (-0.78%) ▼|JPM355.45-6.62 (-1.83%) ▼|KO88.75-0.07 (-0.07%) ▼|LIN481.08-1.11 (-0.23%) ▼|LLY1,142.88-16.72 (-1.44%) ▼|LMT526.66-6.29 (-1.18%) ▼|LOW201.98+0.08 (+0.04%) ▲|LRCX302.14+9.48 (+3.24%) ▲|MA580.05-5.66 (-0.97%) ▼|MCD256.73-2.90 (-1.12%) ▼|MDLZ61.71+0.26 (+0.42%) ▲|MDT94.29+1.19 (+1.28%) ▲|META612.70+2.02 (+0.33%) ▲|MMM168.73+0.42 (+0.25%) ▲|MO69.28-0.22 (-0.31%) ▼|MRK150.76-1.58 (-1.04%) ▼|MS214.63-2.52 (-1.16%) ▼|MSFT500.52-9.60 (-1.88%) ▼|MU999.00+40.84 (+4.26%) ▲|NEE83.76-0.30 (-0.36%) ▼|NFLX79.58-3.09 (-3.74%) ▼|NKE38.31-0.47 (-1.20%) ▼|NOW140.66-4.94 (-3.39%) ▼|NVDA232.00+3.55 (+1.55%) ▲|ORCL157.58+3.54 (+2.30%) ▲|PEP138.67+0.13 (+0.09%) ▲|PFE28.56-0.25 (-0.87%) ▼|PG146.68-0.24 (-0.16%) ▼|PLTR175.86-6.67 (-3.65%) ▼|PM184.44-1.73 (-0.93%) ▼|QCOM168.90+0.33 (+0.20%) ▲|RTX200.02-2.11 (-1.04%) ▼|SBUX105.29-0.53 (-0.50%) ▼|SCHW109.12-1.26 (-1.14%) ▼|SO88.55-0.22 (-0.25%) ▼|SPG212.04+0.52 (+0.25%) ▲|T25.92-0.28 (-1.05%) ▼|TMO612.13-6.30 (-1.02%) ▼|TMUS181.93-6.09 (-3.24%) ▼|TSLA352.69-23.68 (-6.29%) ▼|TXN258.26+4.43 (+1.75%) ▲|UBER75.35-0.61 (-0.80%) ▼|UNH397.02-3.92 (-0.98%) ▼|UNP290.81+1.66 (+0.57%) ▲|UPS102.83-0.67 (-0.65%) ▼|USB63.33-0.20 (-0.31%) ▼|V374.25-4.50 (-1.19%) ▼|VZ50.24-0.36 (-0.70%) ▼|WFC89.06-0.14 (-0.15%) ▼|WMT107.63-0.79 (-0.73%) ▼|XOM160.36-1.85 (-1.14%) ▼|
28.3 C
New York
Friday, September 4, 2026

Tag: antibody

COVID-19 Kits Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges

The Global COVID-19 Kits Market is projected to grow from USD 5.67 billion in 2025 to USD 9.03 billion by 2032, at a CAGR of 6.9%. This market provides essential tools for diagnosing COVID-19 with PCR, antigen, and antibody tests. Rapid innovation, regulatory support, and digital tools enhance market growth.
The Global COVID-19 Kits Market is projected to grow from USD 5.67 billion in 2025 to USD 9.03 billion by 2032, at a CAGR of 6.9%. This market provides essential tools for diagnosing COVID-19 with PCR, antigen, and antibody tests. Rapid innovation, regulatory support, and digital tools enhance market growth.

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company...

Abcentra Announces Appointment of Dr. Peter Libby as a Board Member as it Enters Orticumab’s Phase 2b Trial (FORTIFY)

LOS ANGELES, June 24, 2025 /PRNewswire/ -- Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today announced the appointment...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies...

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...

Cidara Announces Proposed Public Offering of Common Stock

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine’s DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAntibody